Biomarkers in osteosarcoma

Expert Opinion on Medical Diagnostics

Volumn 3, Issue 1, 2009, Pages 13-23

  Kong, Colin ^a   Hansen, Marc F ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Biomarkers; Chemotherapy; High throughput screening; Osteosarcoma

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR; CISPLATIN; COMPLEMENTARY DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; FAS ANTIGEN; FAS LIGAND; IFOSFAMIDE; MATRIX METALLOPROTEINASE; METHOTREXATE; MOLECULAR MARKER; PROTEIN P53; SURVIVIN; TRASTUZUMAB; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER THERAPY; CHROMOSOMAL INSTABILITY; DISEASE CLASSIFICATION; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; METASTASIS; MICROARRAY ANALYSIS; MUTATION; OSTEOSARCOMA; RETINOBLASTOMA; REVIEW; ROTHMUND THOMSON SYNDROME; TELOMERE; TUMOR SUPPRESSOR GENE;

EID: 77953404424     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050802608496     Document Type: Review

References (158)

1. Healey JH, Hoang BH. Editorial comment: cancer biology lessons learned from sarcoma. Clin Orthop Relat Res 2008;466 (9):2029-2030
2. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 2008;26(4):633-638 (Pubitemid 351264359)
3. Marulanda GA, Henderson ER, Johnson DA, et al. Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control 2008;15(1):13-20
4. Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9(4):422-441 (Pubitemid 39014554)
5. Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005;104(10):2214-2221 (Pubitemid 41579969)
6. Daw NC, Billups CA, Rodriguez-Galindo C, et al. Metastatic osteosarcoma. Cancer 2006;106(2):403-412
7. Whelan J, Seddon B, Perisoglou M. Management of osteosarcoma. Curr Treat Options Oncol 2006;7(6):444-455 (Pubitemid 44697782)
8. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16(7):2452-2458 (Pubitemid 28309040)
9. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007;19(4):341-346 (Pubitemid 46883523)
10. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized Phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99(2):112-128
11. Haddy TB, Mosher RB, Dinndorf PA, et al. Second neoplasms in survivors of childhood and adolescent cancer are often treatable. J Adolesc Health 2004;34(4):324-329 (Pubitemid 38369281)
12. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008;134(3):281-297 (Pubitemid 351170066)
13. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19(3):292-315 (Pubitemid 32374371)
14. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy:15-year experience in 789 patients treated at a single institution. Cancer 2006;106(5):1154-1161 (Pubitemid 43297356)
15. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993;72(11):3227-3238
16. Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 1985;82(18):6216-6220 (Pubitemid 16223929)
17. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323(6089):643-646 (Pubitemid 16008560)
18. Lee WH, Bookstein R, Hong F, et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987;235(4794):1394-1399 (Pubitemid 17041661)
19. Weichselbaum RR, Beckett M, Diamond A. Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. Proc Natl Acad Sci USA 1988;85(7):2106-2109 (Pubitemid 24315837)
20. Araki N, Uchida A, Kimura T, et al. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop Relat Res 1991;270:271-277
21. Scholz RB, Kabisch H, Weber B, et al. Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol 1992;9(2):125-137
22. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 1996;271(14):8313- 8320 (Pubitemid 26108665)
23. Baker GL, Landis MW, Hinds PW. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle 2005;4(2):330-338 (Pubitemid 41365343)
24. Cheng L, Rossi F, Fang W, et al. Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16INK4A(+) tumor cells. J Biol Chem 2000;275(39):30317-30325 (Pubitemid 30751347)
25. Ezhevsky SA, Ho A, Becker-Hapak M, et al. Differential regulation of retinoblastoma tumor suppressor protein by G1; cyclin-dependent kinase complexes in vivo Mol Cell Biol 2001;21(14):4773-4784
26. Kato J, Matsushime H, Hiebert SW, et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993;7(3):331-342 (Pubitemid 23139228)
27. Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 1994;54(11):3042-3048 (Pubitemid 24187793)
28. Heinsohn S, Evermann U, Zur Stadt U, et al. Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol 2007;30(5):1205-1214
29. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88(3):323-331 (Pubitemid 27131374)
30. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005;61:44-55 (Pubitemid 40064898)
31. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71(4):747-752
32. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988; 48(18):5358-5362 (Pubitemid 18220645)
33. Porter DE, Holden ST, Steel CM, et al. A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families. J Bone Joint Surg Br 1992;74(6):883-886
34. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Sciencen 1990;250(4985):1233-1238 (Pubitemid 120031831)
35. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002;397:40-52 (Pubitemid 34442014)
36. Iwakuma T, Lozano G, Flores ER. Li-Fraumeni syndrome: a p53 family affair. Cell Cycle 2005;4(7):865-867 (Pubitemid 41359746)
37. Fuchs N, Winkler K. Osteosarcoma. Curr Opin Oncol 1993;5(4):667-671
38. Pompetti F, Rizzo P, Simon RM, et al. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem. 1996;63(1):37-50 (Pubitemid 26329785)
39. Riley T, Sontag E, Chen P, et al. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9(5):402-412 (Pubitemid 351574202)
40. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006;21(3):307-315 (Pubitemid 43163526)
41. Florenes VA, Maelandsmo GM, Forus A, et al. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994;86(17):1297-1302 (Pubitemid 24276791)
42. Miller CW, Aslo A, Won A, et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 1996;122(9):559-565 (Pubitemid 26284557)
43. Lonardo F, Ueda T, Huvos AG, et al. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 1997;79(8):1541-1547 (Pubitemid 27154785)
44. Pakos EE, Kyzas PA, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res 2004;10(18 Pt 1):6208-6214 (Pubitemid 39287528)
45. Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2005;23(7):1483-1490 (Pubitemid 46260036)
46. Kaseta MK, Khaldi L, Gomatos IP, et al. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. J Surg Oncol 2008;97(3):259-266 (Pubitemid 351312167)
47. Pasello M, Michelacci F, Scionti I, et al. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 2008;68(16):6661-6668
48. Huang G, Mills L, Worth LL. Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol Cancer Ther 2007;6(5):1610-1619 (Pubitemid 46954028)
49. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333(21):1380-1385
50. Chan HS, Grogan TM, Haddad G, et al. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 1997;89(22):1706-1715 (Pubitemid 27508195)
51. Hornicek FJ, Gebhardt MC, Wolfe MW, et al. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop Relat Res 2000;373:11-17 (Pubitemid 30225654)
52. Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003;21(3):536-542 (Pubitemid 46606485)
53. Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 2003;98(3):581-589 (Pubitemid 36885999)
54. Schwartz CL, Gorlick R, Teot L, et al. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 2007;25(15):2057-2062 (Pubitemid 46972791)
55. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410(6824):50-56 (Pubitemid 32225831)
56. Raman D, Baugher PJ, Thu YM, et al. Role of chemokines in tumor growth. Cancer Lett 2007;256(2):137-165 (Pubitemid 47418345)
57. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11(7):2561-2567 (Pubitemid 40569454)
58. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 2005;11(2 Pt 1):490-497 (Pubitemid 40116871)
59. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006;19(5):738-745
60. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008;25(3):201-211
61. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77(1):71-78 (Pubitemid 26002739)
62. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17(9):2781-2788 (Pubitemid 29415235)
63. Akatsuka T, Wada T, Kokai Y, et al. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology 2001;60(4):361-366 (Pubitemid 32623452)
64. Maitra A, Wanzer D, Weinberg AG, et al. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001;92(3):677-683 (Pubitemid 32735206)
65. Morris CD, Gorlick R, Huvos G, et al. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop 2001;382:59-65 (Pubitemid 32047430)
66. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94(5):1397-1404 (Pubitemid 34212632)
67. Thomas DG, Giordano TJ, Sanders D, et al. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002;8(3):788-793 (Pubitemid 34742109)
68. Valabrega G, Fagioli F, Corso S, et al. ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. Br J Cancer 2003;88(3):396-400 (Pubitemid 36308150)
69. Zhou H, Randall RL, Brothman AR, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25(1):27-32 (Pubitemid 36070961)
70. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004;40(7):963-970 (Pubitemid 38496251)
71. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004;100(9):1936-1942 (Pubitemid 38529571)
72. Hughes DP, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004;64(6):2047-2053 (Pubitemid 38339452)
73. Tsai JY, Aviv H, Benevenia J, et al. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 2004;22(1):16-24 (Pubitemid 38523956)
74. Hughes DP, Thomas DG, Giordano TJ, et al. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Blood Cancer 2006;46(5):614-623
75. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005;41(9):1349-1361 (Pubitemid 40813013)
76. Taylor SL, Rudland PS, Barraclough R. C-erbB-2 mRNA in breast cancer specimens that exhibit membrane or cytoplasmic immunoreactivity for c-erbB-2. Oncol Res 1999;11(7):311-317
77. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16(2):173-182 (Pubitemid 36245750)
78. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004;10(5):201-204 (Pubitemid 38581790)
79. Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003;46(2):165-186 (Pubitemid 36452345)
80. Fukaya Y, Ishiguro N, Senga T, et al. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol Rep 2005;14(4):847-852
81. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10(2):182-186 (Pubitemid 38524889)
82. Kim MS, Song WS, Cho WH, et al. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 2007;459:229-236 (Pubitemid 46878222)
83. Ferrari S, Zanella L, Alberghini M, et al. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr Blood Cancer 2008;50(4):752-756 (Pubitemid 351354778)
84. Park HR, Jung WW, Bacchini P, et al. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract 2006;202(7):509-515 (Pubitemid 43871944)
85. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58(23):5315-5320 (Pubitemid 28551107)
86. Trieb K, Lehner R, Stulnig T, et al. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003;29(4):379-382 (Pubitemid 36675696)
87. Osaka E, Suzuki T, Osaka S, et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem 2006;39(3):95-100
88. Wang W, Luo H, Wang A. Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol 2006;93(7):578-584 (Pubitemid 43806994)
89. Osaka E, Suzuki T, Osaka S, et al. Survivin expression levels as independent predictors of survival for osteosarcoma patients. J Orthop Res 2007;25(1):116-121 (Pubitemid 46070738)
90. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002;296(5573):1635-1636 (Pubitemid 34579146)
91. Lafleur EA, Koshkina NV, Stewart J, et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004;10(23):8114-8119 (Pubitemid 39587553)
92. Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005;27(11):611-615 (Pubitemid 41697350)
93. Koshkina NV, Khanna C, Mendoza A, et al. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007;5(10):991-999 (Pubitemid 350070755)
94. Worth LL, Lafleur EA, Jia SF, et al. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002;9(4):823-827
95. Gordon N, Koshkina NV, Jia SF, et al. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007;13(15 Pt 1):4503-4510 (Pubitemid 47219720)
96. Duan X, Zhou Z, Jia SF, et al. Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway. Clin Cancer Res 2004;10(2):777-783 (Pubitemid 38174016)
97. Duan X, Jia SF, Koshkina N, et al. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 2006;106(6):1382-1388 (Pubitemid 43363918)
98. Jia SF, Worth LL, Turan M, et al. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. Anticancer Drugs 2002;13(2):155-161 (Pubitemid 34183645)
99. Ando T, Ichikawa J, Okamoto A, et al. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res 2005;23(4):964-969 (Pubitemid 40960051)
100. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 2005;116(3):458-463 (Pubitemid 40993344)
101. Himelstein BP, Asada N, Carlton MR, et al. Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol 1998;31(6):471-474 (Pubitemid 28535913)
102. Bjornland K, Flatmark K, Pettersen S, et al. Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 2005;127(2):151-156 (Pubitemid 41080627)
103. Ferrari C, Benassi S, Ponticelli F, et al. Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years. Acta Orthop Scand 2004;75(4):487-491 (Pubitemid 39179538)
104. Uchibori M, Nishida Y, Nagasaka T, et al. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 2006;28(1):33-42
105. Kang HG, Kim HS, Kim KJ, et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res 2007;25(5):696-702 (Pubitemid 46730522)
106. Dass CR, Nadesapillai AP, Robin D, et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 2005;22(8):643-652 (Pubitemid 44259525)
107. Scheel C, Schaefer KL, Jauch A, et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 2001;20(29):3835-3844 (Pubitemid 32646194)
108. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol 2000;1(1):72-76
109. Neumann AA, Reddel RR. Telomere maintenance and cancer-look, no telomerase. Nat Rev Cancer 2002;2(11):879-884
110. Sotillo-Pineiro E, Sierrasesumaga L, Patinno-Garcia A. Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatr Res 2004;55(2):231-235 (Pubitemid 38121000)
111. Ulaner GA, Hoffman AR, Otero J, et al. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004;41(2):155-162 (Pubitemid 39096741)
112. Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 2003;63(8):1759-1763 (Pubitemid 36469314)
113. Hackett JA, Feldser DM, Greider CW. Telomere dysfunction increases mutation rate and genomic instability. Cell 2001;106(3):275-286 (Pubitemid 32772612)
114. Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 2002;21(4):619-626 (Pubitemid 34146262)
115. Kitao S, Lindor NM, Shiratori M, et al. Rothmund-thomson syndrome responsible gene, RECQL4: genomic structure and products. Genomics 1999;613:268-276
116. Kitao S, Shimamoto A, Goto M, et al. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet 1999;22 (1):82-84 (Pubitemid 29214810)
117. Lindor NM, Furuichi Y, Kitao S, et al. Rothmund-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndrome. Am J Med Genet 2000;90(3):223-228 (Pubitemid 30051869)
118. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 2003;95(9):669-674 (Pubitemid 36603723)
119. Nishijo K, Nakayama T, Aoyama T, et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer 2004;111(3):367-372 (Pubitemid 38998816)
120. Wang LL. Biology of osteogenic sarcoma. Cancer J 2005;11(4):294-305 (Pubitemid 44698796)
121. Wang LL, Levy ML, Lewis RA, et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 2001;102(1):11-17 (Pubitemid 32623258)
122. Macsai CE, Foster BK, Xian CJ. Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. J Cell Physiol 2008;215(3):578-587 (Pubitemid 351632678)
123. Macdonald BT, Semenov MV, He X. SnapShot:Wnt/beta-catenin signaling. Cell 2007;131(6):1204
124. Hoang BH, Kubo T, Healey JH, et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64(8):2734-2739 (Pubitemid 38500609)
125. Lee N, Smolarz AJ, Olson S, et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 2007;97(11):1552-1559 (Pubitemid 350175854)
126. Chen K, Fallen S, Abaan HO, et al. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Blood Cancer 2008;51(3):349-355
127. Hoang BH, Kubo T, Healey JH, et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004;109(1):106-111 (Pubitemid 38160669)
128. Feuk L, Marshall CR, Wintle RF, et al. Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet 2006;15(Spec No 1):R57-66
129. Forus A, Weghuis DO, Smeets D, et al. Comparative genomic hybridization analysis of human sarcomas:II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chromosomes Cancer 1995;14(1):15-21
130. Tarkkanen M, Karhu R, Kallioniemi A, et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 1995;55(6):1334-1338
131. Tarkkanen M, Bohling T, Gamberi G, et al. Comparative genomic hybridization of low-grade central osteosarcoma. Mod Pathol 1998;11(5):421-426 (Pubitemid 28224442)
132. Tarkkanen M, Elomaa I, Blomqvist C, et al. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer 1999;84(2):114-121 (Pubitemid 29133820)
133. Stock C, Kager L, Fink FM, et al. Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer 2000;28(3):329-336 (Pubitemid 30399563)
134. Zielenska M, Bayani J, Pandita A, et al. Comparative genomic hybridization analysis identifies gains of 1p35 approximately p36 and chromosome 19 in osteosarcoma. Cancer Genet Cytogenet 2001;130(1):14-21 (Pubitemid 32979161)
135. Ozaki T, Schaefer KL, Wai D, et al. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 2002;102(4):355-365 (Pubitemid 35265876)
136. Hattinger CM, Reverter-Branchat G, Remondini D, et al. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol 2003;82(9):483-493 (Pubitemid 37266047)
137. Squire JA, Pei J, Marrano P, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 2003;38(3):215-225 (Pubitemid 37259638)
138. Lau CC, Harris CP, Lu XY, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 2004;39(1):11-21 (Pubitemid 37475248)
139. Man TK, Lu XY, Jaeweon K, et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 2004;4:45 (Pubitemid 40180241)
140. Zielenska M, Marrano P, Thorner P, et al. High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. Cytogenet Genome Res 2004;107(1-2):77-82 (Pubitemid 39140348)
141. Atiye J, Wolf M, Kaur S, et al. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 2005;42(2):158-163 (Pubitemid 40094099)
142. Wolf M, El-Rifai W, Tarkkanen M, et al. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet 2000;123(2):128-132 (Pubitemid 32012494)
143. Nakano T, Tani M, Ishibashi Y, et al. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis 2003;20(7):665-674 (Pubitemid 37463904)
144. Zucchini C, Bianchini M, Valvassori L, et al. Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. Bone 2004;34(4):672-679 (Pubitemid 38393803)
145. Mandal D, Srivastava A, Mahlum E, et al. Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene 2007;386(1-2):131-138 (Pubitemid 44932210)
146. Mori K, Berreur M, Blanchard F, et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep 2007;18(6):1365-1371
147. Zucchini C, Rocchi A, Manara MC, et al. Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines. Int J Oncol 2008;32(1):17-31 (Pubitemid 351176058)
148. Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001;61(9):3750-3759 (Pubitemid 32694989)
149. Ochi K, Daigo Y, Katagiri T, et al. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 2004;24(3):647-655
150. Man TK, Chintagumpala M, Visvanathan J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 2005;65(18):8142-8150 (Pubitemid 41330577)
151. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005;65(5):1748-1754 (Pubitemid 40478600)
152. Savage SA, Woodson K, Walk E, et al. Analysis of genes critical for growth regulation identifies Insulin-like Growth Factor 2 Receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev 2007;16(8):1667-1674 (Pubitemid 47294836)
153. Stewart SA, Weinberg RA. Telomeres: cancer to human aging. Annu Rev Cell Dev Biol 2006;22:531-557 (Pubitemid 44778007)
154. Li Y, Dang TA, Shen J, et al. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics 2006;6(11):3426-3435 (Pubitemid 43886158)
155. Kawai A, Kondo T, Suehara Y, et al. Global Protein-expression Analysis of Bone and Soft Tissue Sarcomas. Clin Orthop Relat Res 2008;466(9):2099-2106
156. Niforou KM, Anagnostopoulos AK, Vougas K, et al. The proteome profile of the human osteosarcoma U2OS cell line. Cancer Genomics Proteomics 2008;5(1):63-78
157. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314(5797):268-274
158. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318(5853):1108-1113 (Pubitemid 350134889)